HB
HZNP

Homrich & Berg’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Homrich & Berg’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,132
Closed -$243K – 416
2020
Q3 		$243K Buy
+3,132
New +$215K 0.01% 293

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Homrich & Berg's HZNP Position: Q4 2020 in Review

Homrich & Berg sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 3,132 shares — an estimated $243K sold.

Homrich & Berg first reported a position in HZNP in Q3 2020 and held it in 1 quarter. The position peaked at $243K in Q3 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

  • Homrich & Berg reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Homrich & Berg sold 3,132 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $243K.
  • Homrich & Berg first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 1 quarter.
  • Homrich & Berg's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $243K in Q3 2020.
  • 497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Homrich & Berg's 13F filing for Q4 2020, filed 16 Feb 2021.